Using Circulating Tumor DNA as a Novel Biomarker to Screen and Diagnose Colorectal Cancer: A Meta-Analysis

Liang, Min; Chen, Jinghua; Yu, Meihong; Liu, Deliang

doi:10.3390/jcm12020408

Cited by 12 publications

(4 citation statements)

References 120 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because its changes occur even before the occurrence of tumors, it is theoretically ideal for early screening of tumors[ 10 , 42 ]. SEPT9 methylation was the first methylated marker approved by the FDA for screening CRC using plasma samples, with a diagnostic sensitivity of 0.679 (95%CI: 0.622-0.732) and specificity of 0.904 (95%CI: 0.881-0.923)[ 43 ]. However, it is no longer recommended by most guidelines because it is less sensitive than other current tests[ 44 ].…”

Section: Discussionmentioning

confidence: 99%

Diagnostic value of methylated branched chain amino acid transaminase 1/IKAROS family zinc finger 1 for colorectal cancer

Xu,

Yu,

Pan

et al. 2023

World J Gastroenterol

View full text Add to dashboard Cite

The liver is one of the organs most commonly involved in metastatic disease, especially due to its unique vascularization. It’s well known that liver metastases represent the most common hepatic malignant tumors. From a practical point of view, it’s of utmost importance to evaluate the presence of liver metastases when staging oncologic patients, to select the best treatment possible, and finally to predict the overall prognosis. In the past few years, imaging techniques have gained a central role in identifying liver metastases, thanks to ultrasonography, contrast-enhanced computed tomography (CT), and magnetic resonance imaging (MRI). All these techniques, especially CT and MRI, can be considered the non-invasive reference standard techniques for the assessment of liver involvement by metastases. On the other hand, the liver can be affected by different focal lesions, sometimes benign, and sometimes malignant. On these bases, radiologists should face the differential diagnosis between benign and secondary lesions to correctly allocate patients to the best management. Considering the above-mentioned principles, it’s extremely important to underline and refresh the broad spectrum of liver metastases features that can occur in everyday clinical practice. This review aims to summarize the most common imaging features of liver metastases, with a special focus on typical and atypical appearance, by using MRI.

show abstract

Section: Discussionmentioning

confidence: 99%

Diagnostic value of methylated branched chain amino acid transaminase 1/IKAROS family zinc finger 1 for colorectal cancer

Xu,

Yu,

Pan

et al. 2023

World J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…Tests that rely on the detection of circulating tumor DNA (ctDNA), also known as liquid biopsies, are susceptible to vulnerabilities. A study conducted by Min et al (2023) in 2023 demonstrated that quantitative analysis of ctDNA and qualitative investigation of SEPT9 methylation effectively diagnose CRC. According to a study conducted by Perdyan et al (2020) in 2020, ctDNA demonstrated an accuracy of 87.2% and a precision of 99.2% in identifying clinically significant KRAS gene mutations in a group of 206 patients with mCRC.…”

Section: Circulating Tumor Dna (Ctdna)mentioning

confidence: 99%

“…The detection rate for those with CRC stages 0-I using this method ranges from 57% to 64% (Zhao et al, 2020). According to the meta-analysis, individuals with advanced CRC cases were more likely to test positive for methylated SEPT 9 (mSEPT9) than those with early-stage CRC, and the opposite was true for people with early-stage CRC (Min et al, 2023). According to the latest meta-analysis released in 2020, the SEPT9 assay has a specificity of 92% and a sensitivity of 69% for CRC diagnoses (Hariharan and Jenkins, 2020).…”

Section: Septin 9 (Sept9) Gene Methylationmentioning

confidence: 99%

Novel biomarkers used for early diagnosis and tyrosine kinase inhibitors as targeted therapies in colorectal cancer

Jiang,

Zhou,

2023

Front. Pharmacol.

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the third most common and second most lethal type of cancer worldwide, presenting major health risks as well as economic costs to both people and society. CRC survival chances are significantly higher if the cancer is diagnosed and treated early. With the development of molecular biology, numerous initiatives have been undertaken to identify novel biomarkers for the early diagnosis of CRC. Pathological disorders can be diagnosed at a lower cost with the help of biomarkers, which can be detected in stool, blood, and tissue samples. Several lines of evidence suggest that the gut microbiota could be used as a biomarker for CRC screening and treatment. CRC treatment choices include surgical resection, chemotherapy, immunotherapy, gene therapy, and combination therapies. Targeted therapies are a relatively new and promising modality of treatment that has been shown to increase patients’ overall survival (OS) rates and can inhibit cancer cell development. Several small-molecule tyrosine kinase inhibitors (TKIs) are being investigated as potential treatments due to our increasing awareness of CRC’s molecular causes and oncogenic signaling. These compounds may inhibit critical enzymes in controlling signaling pathways, which are crucial for CRC cells’ development, differentiation, proliferation, and survival. On the other hand, only one of the approximately 42 TKIs that demonstrated anti-tumor effects in pre-clinical studies has been licensed for clinical usage in CRC. A significant knowledge gap exists when bringing these tailored medicines into the clinic. As a result, the emphasis of this review is placed on recently discovered biomarkers for early diagnosis as well as tyrosine kinase inhibitors as possible therapy options for CRC.

show abstract

“…The quantitative analysis of cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) involves the assessment of the absolute and relative abundance levels of these fragments in the blood [ 69 ]. A quantitative analysis of cell-free DNA and circulating tumor DNA (ctDNA) has been widely used in other neoplasms for monitoring patients after treatment with curative intent to determine recurrence, residual disease, and, in cases involving transplants, transplant rejection [ 36 ].…”

Section: The Role Of Liquid Biopsy and Cell-free Dna (Cfdna) In Patie...mentioning

confidence: 99%

Cell-Free DNA as a Surveillance Tool for Hepatocellular Carcinoma Patients after Liver Transplant

Manzi

Hoff

Ferreira

et al. 2023

Cancers

View full text Add to dashboard Cite

The liver is the world’s sixth most common primary tumor site, responsible for approximately 5% of all cancers and over 8% of cancer-related deaths. Hepatocellular carcinoma (HCC) is the predominant type of liver cancer, accounting for approximately 75% of all primary liver tumors. A major therapeutic tool for this disease is liver transplantation. Two of the most significant issues in treating HCC are tumor recurrence and graft rejection. Currently, the detection and monitoring of HCC recurrence and graft rejection mainly consist of imaging methods, tissue biopsies, and alpha-fetoprotein (AFP) follow-up. However, they have limited accuracy and precision. One of the many possible components of cfDNA is circulating tumor DNA (ctDNA), which is cfDNA derived from tumor cells. Another important component in transplantation is donor-derived cfDNA (dd-cfDNA), derived from donor tissue. All the components of cfDNA can be analyzed in blood samples as liquid biopsies. These can play a role in determining prognosis, tumor recurrence, and graft rejection, assisting in an overall manner in clinical decision-making in the treatment of HCC.

show abstract

Using Circulating Tumor DNA as a Novel Biomarker to Screen and Diagnose Colorectal Cancer: A Meta-Analysis

Cited by 12 publications

References 120 publications

Diagnostic value of methylated branched chain amino acid transaminase 1/IKAROS family zinc finger 1 for colorectal cancer

Diagnostic value of methylated branched chain amino acid transaminase 1/IKAROS family zinc finger 1 for colorectal cancer

Novel biomarkers used for early diagnosis and tyrosine kinase inhibitors as targeted therapies in colorectal cancer

Cell-Free DNA as a Surveillance Tool for Hepatocellular Carcinoma Patients after Liver Transplant

Contact Info

Product

Resources

About